JP2009543802A5 - - Google Patents

Download PDF

Info

Publication number
JP2009543802A5
JP2009543802A5 JP2009519653A JP2009519653A JP2009543802A5 JP 2009543802 A5 JP2009543802 A5 JP 2009543802A5 JP 2009519653 A JP2009519653 A JP 2009519653A JP 2009519653 A JP2009519653 A JP 2009519653A JP 2009543802 A5 JP2009543802 A5 JP 2009543802A5
Authority
JP
Japan
Prior art keywords
nrr
nhr
acyl
independently
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009519653A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009543802A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/073285 external-priority patent/WO2008008854A2/en
Publication of JP2009543802A publication Critical patent/JP2009543802A/ja
Publication of JP2009543802A5 publication Critical patent/JP2009543802A5/ja
Pending legal-status Critical Current

Links

JP2009519653A 2006-07-11 2007-07-11 医学的疾患の治療のためのジアジン及びトリアジン構造を含むcxcr4アンタゴニスト Pending JP2009543802A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83000606P 2006-07-11 2006-07-11
US81999706P 2006-07-11 2006-07-11
PCT/US2007/073285 WO2008008854A2 (en) 2006-07-11 2007-07-11 Cxcr4 antagonists including diazine and triazine structures for the treatment of medical disorders

Publications (2)

Publication Number Publication Date
JP2009543802A JP2009543802A (ja) 2009-12-10
JP2009543802A5 true JP2009543802A5 (enExample) 2011-09-01

Family

ID=38924159

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009519653A Pending JP2009543802A (ja) 2006-07-11 2007-07-11 医学的疾患の治療のためのジアジン及びトリアジン構造を含むcxcr4アンタゴニスト

Country Status (4)

Country Link
US (1) US8080659B2 (enExample)
EP (1) EP2041067A4 (enExample)
JP (1) JP2009543802A (enExample)
WO (1) WO2008008854A2 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1838321A4 (en) * 2005-01-07 2009-03-18 Univ Emory CXCR4 ANTAGONISTS FOR THE TREATMENT OF HIV INFECTION
US8338448B2 (en) 2008-03-28 2012-12-25 Altiris Therapeutics, Inc. Chemokine receptor modulators
US20120294803A1 (en) * 2010-01-27 2012-11-22 Emory University Cxcr4 antagonists for imaging of cancer and inflammatory disorders
EP2380596A1 (en) 2010-04-20 2011-10-26 Technische Universität München Cyclopentapeptide derivatives and uses thereof
EP2380597A1 (en) 2010-04-20 2011-10-26 Technische Universität München Cyclopeptide derivatives and uses thereof
US8921328B2 (en) 2010-09-14 2014-12-30 Glycomimetics, Inc. E-selectin antagonists
MX365242B (es) 2011-05-16 2019-05-28 Genzyme Corp El uso del antagonista cxcr4: 1,1´-[1,4-fenileno-bis-(metileno)-bi s-1, 4, 8, 11-tetraazaciclotetradecano (plerixaflor) para el tratamiento del síndrome de whim.
WO2013060865A1 (en) 2011-10-28 2013-05-02 Galderma Research & Development New leukocyte infiltrate markers for rosacea and uses thereof
ES2634939T3 (es) 2011-11-07 2017-09-29 Emory University Compuestos que contienen aminas tricíclicas para el tratamiento o prevención de síntomas asociados con la disfunción endocrina
EP3296310A1 (en) 2011-12-22 2018-03-21 GlycoMimetics, Inc. E-selectin antagonist compounds, compositions, and methods of use
JP6392773B2 (ja) 2012-12-07 2018-09-19 グリコミメティクス, インコーポレイテッド 造血細胞の動員のためにe−セレクチンアンタゴニストを使用する化合物、組成物および方法
HUE044571T2 (hu) 2014-06-06 2019-11-28 Univ Muenchen Tech Módosított ciklopentapeptidek és alkalmazásaik
HUE045542T2 (hu) 2014-12-03 2019-12-30 Glycomimetics Inc E-szelektinek és CXCR4 kemokin receptorok heterobifunkcionális inhibitorai
US10434195B2 (en) * 2015-08-03 2019-10-08 Emory University Methylsulfonamide derivatives and uses related thereto
US11291678B2 (en) 2016-03-02 2022-04-05 Glycomimetics, Inc Methods for the treatment and/or prevention of cardiovascular disease by inhibition of E-selectin
JP2019524791A (ja) 2016-08-08 2019-09-05 グリコミメティクス, インコーポレイテッド E−セレクチンの阻害剤もしくはcxcr4の阻害剤との、またはe−セレクチンおよびcxcr4両方のヘテロ二機能性阻害剤とのt細胞チェックポイント阻害剤の組み合わせ
WO2018068010A1 (en) 2016-10-07 2018-04-12 Glycomimetics, Inc. Highly potent multimeric e-selectin antagonists
MA46589A (fr) 2016-10-24 2019-08-28 Yumanity Therapeutics Inc Composés et utilisations de ces derniers
MA47212A (fr) 2017-01-06 2019-11-13 Yumanity Therapeutics Inc Méthodes de traitement de troubles neurologiques
US11197877B2 (en) 2017-03-15 2021-12-14 Glycomimetics. Inc. Galactopyranosyl-cyclohexyl derivauves as E-selectin antagonists
CN109553604B (zh) * 2017-09-25 2021-08-27 盛世泰科生物医药技术(苏州)有限公司 4-氨基嘧啶衍生物作cxcr4抑制剂及其应用
WO2019084157A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. COMPOUNDS AND USES THEREOF
EP3717013A1 (en) 2017-11-30 2020-10-07 GlycoMimetics, Inc. Methods of mobilizing marrow infiltrating lymphocytes and uses thereof
KR20200104889A (ko) 2017-12-29 2020-09-04 글리코미메틱스, 인크. E-셀렉틴 및 갈렉틴-3의 이종이기능성 억제제
AU2019230013A1 (en) 2018-03-05 2020-09-10 Glycomimetics, Inc. Methods for treating acute myeloid leukemia and related conditions
CN112312913B (zh) 2018-03-23 2024-03-08 詹森药业有限公司 化合物和其用途
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
MX2021008903A (es) 2019-01-24 2021-11-04 Yumanity Therapeutics Inc Compuestos y usos de los mismos.
JP2022526890A (ja) * 2019-03-22 2022-05-27 ユマニティ セラピューティクス,インコーポレーテッド 化合物及びその使用
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US776465A (en) * 1904-04-15 1904-11-29 Charles A Gildemeyer Spigot.
US5993817A (en) 1995-01-23 1999-11-30 Xenotech Method to ameliorate osteolysis and metastasis
US6358915B1 (en) 1995-03-07 2002-03-19 George Washington University Methods for inhibiting metastasis
AU6390696A (en) 1995-06-20 1997-01-22 Trustees Of Boston University Hypoxia-responsive adhesion molecules, specific antibodies, nd their uses
US6344545B1 (en) 1996-06-14 2002-02-05 Progenics Pharmaceuticals, Inc. Method for preventing HIV-1 infection of CD4+ cells
US5922676A (en) 1996-09-20 1999-07-13 The Burnham Institute Methods of inhibiting cancer by using superfibronectin
US5874438A (en) 1996-10-11 1999-02-23 Bayer Aktiengesellschaft 2,2'-bridged bis-2,4-diaminoquinazolines
US6534626B1 (en) 1997-12-01 2003-03-18 The United States Of America As Represented By The Department Of Health & Human Services Chemokine variants
AU762472B2 (en) 1998-03-13 2003-06-26 University Of British Columbia, The Therapeutic chemokine receptor antagonists
CA2327530A1 (en) 1998-05-05 1999-11-11 Adherex Technologies, Inc. Compounds and methods for modulating nonclassical cadherin-mediated functions
CA2319153A1 (en) * 1998-06-08 1999-12-16 Advanced Medicine, Inc. Novel sodium channel drugs and uses
US6420354B1 (en) * 1998-06-08 2002-07-16 Advanced Medicine, Inc. Sodium channel drugs and uses
EP1050583A4 (en) 1998-11-24 2005-02-02 Hisamitsu Pharmaceutical Co INHIBITORS OF HIV INFECTIONS
US6750348B1 (en) 1999-03-24 2004-06-15 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
IL145401A0 (en) 1999-03-24 2002-06-30 Anormed Inc Chemokine receptor binding heterocyclic compounds
EP2275447A1 (en) 1999-11-24 2011-01-19 Schering Corporation Methods of inhibiting metastasis
US20030220482A1 (en) 2000-02-03 2003-11-27 Ziwei Huang Novel peptide antagonist of CXCR4 derived from the N-terminus of the viral chemokine vMIP-II
WO2001070727A1 (en) * 2000-03-23 2001-09-27 Sanofi-Synthelabo 2-(arylalkylamino)pyrimidone derivatives and 2-(heteroarylalkylamino)pyrimidone derivatives
AU5811001A (en) 2000-05-09 2001-11-20 Univ British Columbia Cxcr4 antagonist treatment of hematopoietic cells
WO2002002516A2 (en) * 2000-06-30 2002-01-10 Thomas Jefferson University Inhibitors of hiv integrase
CN1630517A (zh) 2001-05-24 2005-06-22 吴羽化学工业株式会社 包含含氮化合物的具有cxcr4拮抗作用的药物
WO2003029218A1 (en) 2001-09-28 2003-04-10 Kureha Chemical Industry Company, Limited Novel nitrogenous compound and use thereof
US7354932B2 (en) 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
WO2004020462A1 (ja) 2002-08-27 2004-03-11 Fujii, Nobutaka Cxcr4拮抗薬およびその用途
DE10240064A1 (de) 2002-08-30 2004-03-11 Universitätsklinikum Freiburg CXCR4-Rezeptor-Antagonisten
US20040132642A1 (en) 2002-11-12 2004-07-08 Government Of The U.S.A., Represented By The Secretary, Dept. Of Health & Human Services Methods of inhibiting metastasis or growth of a tumor cell
US20050002939A1 (en) 2002-12-23 2005-01-06 Albert Zlotnik Tumor killing/tumor regression using CXCR4 antagonists
CA2520406A1 (en) 2003-03-27 2004-10-14 Emory University Cxcr4 antagonists and methods of their use
WO2004091518A2 (en) 2003-04-11 2004-10-28 Anormed Inc. Cxcr4 chemokine receptor binding compounds
AU2004232361A1 (en) 2003-04-22 2004-11-04 Anormed Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
DK1687297T3 (da) * 2003-11-24 2014-09-22 Prometic Biosciences Inc Triazindimerer til behandling af autoimmunsygdomme
GB0405193D0 (en) * 2004-03-08 2004-04-21 Medical Res Council Compounds
RU2007130077A (ru) * 2005-01-07 2009-02-20 Эмори Юниверсити (Us) Антагонисты cxcr4 и их применение для лечения вич-инфекции
EP1838321A4 (en) 2005-01-07 2009-03-18 Univ Emory CXCR4 ANTAGONISTS FOR THE TREATMENT OF HIV INFECTION
US20080227799A1 (en) 2006-07-11 2008-09-18 Liotta Dennis C CXCR4 Antagonists Including Heteroatoms for the Treatment of Medical Disorders

Similar Documents

Publication Publication Date Title
JP2009543802A5 (enExample)
JP2015508103A5 (enExample)
JP2018158926A5 (enExample)
JP2009502743A5 (enExample)
JP2016506916A5 (enExample)
JP2010524932A5 (enExample)
JP2014193925A5 (enExample)
JP2009535307A5 (enExample)
JP2008525416A5 (enExample)
JP2016006096A5 (enExample)
JP2015505296A5 (enExample)
JP2005523922A5 (enExample)
JP2013518107A5 (enExample)
JP2016514192A5 (enExample)
JP2009536221A5 (enExample)
JP2008539267A5 (enExample)
JP2013507423A5 (enExample)
JP2010077141A5 (enExample)
JP2012519691A5 (enExample)
JP2013544276A5 (enExample)
JP2015529228A5 (enExample)
JP2017528475A5 (enExample)
JP2009541225A5 (enExample)
RU2015149527A (ru) Производные доластатина 10 и ауристатинов
JP2009500423A5 (enExample)